Omega-3s tame inflammation in elderly COVID-19 patients
October 13, 2021
Those who received an intravenous infusion had significant decreases from baseline to end of treatment in the neutrophil-to-lymphocyte ratio.
PRESERVED-HF: Dapagliflozin improves physical limitations in patients with HFpEF
September 14, 2021
The SGLT2 inhibitor dapagliflozin boosted KCCQ scores and 6-minute walk distance in HFpEF patients in a 324-patient randomized trial.
Two swings, two misses with colchicine, Vascepa in COVID-19
September 1, 2021
The study cohorts varied from healthcare and public workers at high risk for infection to individuals already hospitalized with COVID-19.
EMPEROR-Preserved spouts torrent of reports on empagliflozin treatment of HFpEF
August 31, 2021
The primary report from EMPEROR-Preserved on using empagliflozin to treat patients with HFpEF arrived with four other analyses published in its wake.
SGLT2 inhibitor use rising in patients with DKD
August 23, 2021
Use of SGLT2 inhibitors in patients with type 2 diabetes rose sharply in 2019 and early 2020. GLP-1 RA use also showed recent gains.
Empagliflozin gets HFrEF approval from FDA
August 19, 2021
The SGLT2 inhibitor empagliflozin (Jardiance) becomes the second agent from this class to get a heart failure indication regardless of diabetes status.
Statins again linked to lower COVID-19 mortality
July 21, 2021
Patients hospitalized for COVID-19 who had been taking statins had a substantially lower risk of death and severe outcomes than those who weren’t in a large observational study.
DOACs linked to lower mortality than vitamin K antagonist: 3-year TAVR registry
July 16, 2021
Mortality and bleeding advantage favors DOACs over VKA in TAVR patients who are candidates for anticoagulation.
New AHA/ASA guideline on secondary stroke prevention
May 27, 2021
Identifying the cause of a first stroke or transient ischemic attack is key to developing strategies to prevent repeat events, the AHA/ASA says in an updated clinical practice guideline.
PARADISE-MI: Sacubitril/valsartan can’t beat ramipril in patients with acute MI
May 15, 2021
When treating patients with no history of heart failure within days of an acute myocardial infarction, sacubitril/valsartan showed safety but no clear superiority to ramipril.